articleThe LancetJun 1, 2009Closed access

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

PHPhilip HomeSPStuart PocockHBHenning Beck‐NielsenPCPaula CurtisRGRamón Gomis

Newcastle University · London School of Hygiene & Tropical Medicine · +6 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,395
total citations
FWCI
85.68
Percentile
100%
References
23
Citations per year

Authors

9

Topics & keywords

Topics
Keywords
  • Rosiglitazone
  • Medicine
  • Sulfonylurea
  • Metformin
  • Type 2 diabetes
  • Internal medicine
  • Hazard ratio
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding